Onset and progression of pathologic atrophy in Huntington disease: A longitudinal MR imaging study

American Journal of Neuroradiology

Volumn 31, Issue 6, 2010, Pages 1036-1041

  Hobbs, N Z ^a   Barnes, J ^a   Frost, C ^a,b   Henley, S M D ^a   Wild, E J ^a   Macdonald, K ^a   Barker, R A ^c   Scahill, R I ^a   Fox, N C ^a,d   Tabrizi, S J ^a,d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; BRAIN ATROPHY; BRAIN LATERAL VENTRICLE; BRAIN SIZE; BRAIN VENTRICLE DILATATION; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISEASE COURSE; DISEASE DURATION; DISEASE MARKER; EARLY DIAGNOSIS; HUMAN; HUNTINGTON CHOREA; LATERAL BRAIN VENTRICLE; LONGITUDINAL STUDY; MALE; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; OUTCOME ASSESSMENT; ADULT; ATROPHY; FEMALE; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; YOUNG ADULT;

ADULT; AGE OF ONSET; AGED; ATROPHY; CAUDATE NUCLEUS; DISEASE PROGRESSION; FEMALE; HUMANS; HUNTINGTON DISEASE; LATERAL VENTRICLES; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77953510734     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: 10.3174/ajnr.A2018     Document Type: Article

References (20)

1. Handley OJ, Naji JJ, Dunnett SB, et al. Pharmaceutical, cellular and genetic therapies for Huntington's disease. Clin Sci (Lond) 2006;110:73-88 (Pubitemid 43059046)
2. Fox NC, Black RS, Gilman S, et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurol 2005;64:1563-72
3. Henley SM, Wild EJ, Hobbs NZ, et al. Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease. Mov Disord 2009;2:932-36
4. Aylward EH. Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease. Brain Res Bull 2007;72:152-58
5. Paulsen JS, Hayden M, Stout JC, et al. Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol 2006;63:883-90
6. Aylward EH, Sparks BF, Field KM, et al. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurol 2004;63:66-72
7. Hobbs NZ, Henley SM, Wild EJ, et al. Automated quantification of caudate atrophy by local registration of serial MRI: evaluation and application in Huntington's disease. Neuroimage 2009;47:1659-65
8. Rosas HD, Salat DH, Lee SY, et al. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain 2008;131:1057-68
9. Ruocco HH, Lopes-Cendes I, Li LM, et al. Striatal and extrastriatal atrophy in Huntington's disease and its relationship with length of the CAG repeat. Braz J Med Biol Res 2006;39:1129-36
10. Ciarmiello A, Cannella M, Lastoria S, et al. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J Nucl Med 2006;47:215-22
11. Squitieri F, Cannella M, Simonelli M, et al. Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington's disease. CNS Neurosci Ther 2009;15:1-11
12. Henley SM, Wild EJ, Hobbs NZ, et al. Defective emotion recognition in early HDis neuropsychologically and anatomically generic. Neuropsychologia 2008; 46:2152-60. Epub 2008 Mar 6
13. Unified Huntington's Disease Rating Scale: reliability and consistency-Huntington Study Group. Mov Disord 1996;11:136-42
14. Shoulson I, Fahn S. Huntington disease: clinical care and evaluation. Neurology 1979;29:1-3 (Pubitemid 9051179)
15. Freeborough PA, Fox NC, Kitney RI. Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans. Comput Methods Programs Biomed 1997;53:15-25
16. Mazziotta JC, Toga AW, Evans A, et al. A probabilistic atlas of the human brain: theory and rationale for its development - The International Consortium for Brain Mapping (ICBM). Neuroimage 1995;2:89-101
17. Scahill RI, Frost C, Jenkins R, et al. A longitudinal study of brain volume changes in normal aging using serial registered magnetic resonance imaging. Arch Neurol 2003;60:989-94
18. Whitwell JL, Crum WR, Watt HC, et al. Normalization of cerebral volumes by use of intracranial volume: implications for longitudinal quantitative MR imaging. AJNR Am J Neuroradiol 2001;22:1483-89
19. Fennema-Notestine C, Archibald SL, Jacobson MW, et al. In vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington disease. Neurology 2004;63:989-95
20. Langbehn DR, Brinkman RR, Falush D, et al. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet 2004;65:267-77